SMC backs five new medicines for NHS use
Servier’s Lonsurf and AstraZeneca’s Calquence are among the positive decisions
Read Moreby Lucy Parsons | Jun 8, 2021 | News | 0
Servier’s Lonsurf and AstraZeneca’s Calquence are among the positive decisions
Read Moreby Lucy Parsons | Mar 18, 2021 | News | 0
Recommendation offers new chemotherapy-free treatment options for these patients
Read Moreby Lucy Parsons | Jan 25, 2021 | News | 0
BTK inhibitor demonstrated non-inferior progression-free survival compared to Imbruvica
Read Moreby Selina McKee | Dec 8, 2020 | News | 0
The recommendations are positive for a select population of patients with CLL
Read Moreby Selina McKee | Dec 7, 2020 | News | 0
Patients with relapsed or refractory mantle cell lymphoma (MCL) treated with AstraZeneca’s Calquence remained progression free for a median of 22 months
Read Moreby Lucy Parsons | Nov 10, 2020 | News | 0
BTK inhibitor approved based on results from two phase III trials
Read Moreby Selina McKee | Jul 27, 2020 | News | 0
Recommendations include the first antibody-drug conjugate for multiple myeloma patients with limited treatment options
Read Moreby Selina McKee | Jun 8, 2020 | News | 0
Improved markers of inflammation and reduced oxygen requirements were seen in most patients
Read Moreby Selina McKee | Apr 14, 2020 | News | 0
The moves follows ‘strong scientific evidence’ indicating the role of the BTK pathway in the production of inflammatory cytokines
Read Moreby Selina McKee | Dec 9, 2019 | News | 0
The drug demonstrates “remarkable efficacy”, says AZ’ José Baselga
Read Moreby Anna Smith | Aug 14, 2019 | News | 0
The drug has been approved for chronic lymphocytic leukaemia.
Read Moreby Selina McKee | Jun 17, 2019 | News | 0
A new filing for the drug as a treatment for relapsed or refractory chronic lymphocytic leukaemia is expected later this year
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
